SAM #HT9402-27-Q-9101

DHA requests quotes for dry-eye and oral testosterone medications under formulary review

The Defense Health Agency is requesting pharmaceutical quotes for products under review for its Uniform Formulary. - Government buyer: Defense Health Agency (DHA), for the Department of War and the Military Health System. - Opportunity: RFQ HT9402-27-Q-9101; quotes may inform Uniform Formulary agreements. - Products under review: - Dry-eye ophthalmics: Cequa, Eysuvis, Miebo, Tryptyr, Tyrvaya, Verkazia, Vevye, and Xiidra. - Oral testosterone replacement therapies: Jatenzo, Kyzatrex, and Tlando. - Manufacturers and vendors: The notice summary does not identify manufacturers or resellers. Product quantities and part numbers are also not provided. - Notable requirement: Products are being considered for formulary placement; the notice indicates that resulting agreements depend on the Uniform Formulary decision.

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed:

a. Ophthalmic - Dry Eye

Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra

b. Testosterone Replacement Therapy - Orals

Jatenzo Kyzatrex Tlando

The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Additional Links:http://health.mil/PandT

View original listing